Gut bacteria may trigger type 2 diabetes by converting dietary nutrients into a compound called TMAO that activates immune signaling and causes inflammation, according to a 2026 review in International Immunopharmacology. When you eat foods containing choline, betaine, or carnitine, your gut bacteria produce trimethylamine (TMA), which your liver converts to TMAO. This TMAO appears to activate a protein called IRAK4 that amplifies inflammation and interferes with insulin function, potentially contributing to diabetes development.
Scientists are discovering that type 2 diabetes might be connected to how our gut bacteria process certain foods. When we eat foods containing choline, betaine, and carnitine, our gut bacteria create a substance called TMA, which the liver converts to TMAO. According to Gram Research analysis, this TMAO may trigger inflammation and make it harder for our bodies to use insulin properly. Researchers are also studying a protein called IRAK4 that seems to amplify this inflammatory response. While most evidence comes from lab studies so far, this discovery opens new possibilities for treating diabetes by targeting gut bacteria or blocking specific inflammatory pathways.
Key Statistics
A 2026 review in International Immunopharmacology identified that gut bacteria convert dietary choline, betaine, and carnitine into trimethylamine (TMA), which the liver transforms into TMAO, a compound linked to inflammation and insulin resistance in type 2 diabetes.
According to Gram Research analysis of current evidence, TMAO activates IRAK4 signaling, which triggers inflammatory pathways (NF-kB and MAPK) that interfere with insulin signaling and glucose metabolism in type 2 diabetes.
The 2026 review highlights that while TMAO’s role in cardiovascular disease is well-established, its connection to type 2 diabetes through the IRAK4 pathway remains largely unproven in human studies, with most evidence coming from laboratory research.
The Quick Take
- What they studied: How gut bacteria and their byproducts might cause inflammation and insulin resistance in type 2 diabetes, focusing on two key players: a bacterial compound called TMAO and a protein called IRAK4 that controls immune responses.
- Who participated: This is a review article that examined existing research rather than conducting a new study with human participants. Scientists analyzed findings from laboratory and animal studies to understand the connections between gut bacteria, inflammation, and diabetes.
- Key finding: Gut bacteria convert nutrients from food into TMA, which becomes TMAO in the liver. This TMAO appears to activate IRAK4 and trigger inflammation that interferes with how the body uses insulin, potentially contributing to type 2 diabetes development.
- What it means for you: This research suggests that managing what you eat and your gut bacteria composition might help prevent or manage type 2 diabetes. However, these findings are mostly from lab studies, so more human research is needed before doctors can recommend specific treatments based on TMAO levels.
The Research Details
This is a review article, meaning scientists examined and summarized existing research rather than conducting their own experiment with participants. The authors looked at current evidence from laboratory studies and animal research to understand how gut bacteria, TMAO, and a protein called IRAK4 work together in type 2 diabetes.
The researchers focused on a specific pathway: when you eat certain foods like eggs, red meat, or supplements containing choline, betaine, or carnitine, your gut bacteria break these down into trimethylamine (TMA). Your liver then converts TMA into trimethylamine N-oxide (TMAO). The review examined how TMAO might activate IRAK4, a protein that controls immune responses, leading to inflammation and insulin resistance.
By reviewing multiple studies, the authors identified gaps in current knowledge and suggested new treatment approaches, including drugs that block IRAK4, methods to reduce bacterial TMA production, and interventions targeting the enzyme FMO3 that converts TMA to TMAO.
Understanding the connection between gut bacteria and diabetes is important because it could lead to new ways to prevent and treat the disease. Instead of only managing blood sugar with medications, doctors might be able to target the root cause: the inflammatory process triggered by gut bacteria and TMAO. This approach could be especially valuable because type 2 diabetes affects hundreds of millions of people worldwide and current treatments don’t work equally well for everyone.
This is a review article that synthesizes existing research rather than presenting new experimental data. The strength of the conclusions depends on the quality of the studies reviewed, most of which are laboratory or animal studies rather than human trials. The authors acknowledge important limitations: inconsistent findings about TMAO in different studies, differences in gut bacteria between individuals, and lack of sufficient human validation. Readers should understand that while the proposed mechanisms are scientifically plausible, direct proof in humans is still limited.
What the Results Show
The review identifies a potential chain of events in type 2 diabetes: certain dietary nutrients are converted by gut bacteria into TMA, which the liver transforms into TMAO. This TMAO appears to activate IRAK4, a protein that controls immune signaling. When IRAK4 is activated, it triggers inflammatory pathways (NF-kB and MAPK signaling) that interfere with insulin signaling and glucose metabolism.
The authors emphasize that this TMA-IRAK4 axis represents a link between diet, gut bacteria, immune function, and metabolic disease. The inflammatory state created by this pathway may explain why some people develop insulin resistance, where their bodies stop responding properly to insulin even when it is present.
The review also highlights that this mechanism connects three previously separate areas of research: the role of gut bacteria in health, the inflammatory nature of type 2 diabetes, and how the immune system controls metabolism. This integrated view suggests that targeting any point in this chain could potentially help treat diabetes.
The review identifies several related findings: TMAO has been linked to cardiovascular problems in addition to diabetes, suggesting that managing TMAO levels might benefit heart health as well. The authors note that individual differences in gut bacteria composition mean that people respond differently to the same foods, which could explain why some people develop diabetes while others do not. The review also discusses how FMO3, the liver enzyme that creates TMAO, varies between individuals, which could affect how much TMAO each person produces from the same diet.
This research builds on decades of work showing that type 2 diabetes involves chronic inflammation, not just high blood sugar. Previous studies established that gut bacteria influence metabolism and immune function. This review connects these findings by proposing a specific mechanism: the TMA-TMAO-IRAK4 pathway. The authors note that while TMAO has been studied in cardiovascular disease for years, its role in diabetes is newer and less well understood. This review represents an emerging consensus that gut bacteria and their metabolic byproducts play a central role in metabolic diseases.
The authors identify several important limitations. Most evidence comes from laboratory experiments and animal studies, not human trials, so the findings may not apply directly to people. Different studies report inconsistent results about TMAO, possibly because people have different gut bacteria and genetic backgrounds. The review notes that we still don’t fully understand how TMAO and IRAK4 interact in humans. Additionally, the complexity of the gut microbiome means that targeting one pathway might have unexpected effects on other bacterial species and metabolic processes. The authors emphasize that more human studies are needed before new treatments can be recommended.
The Bottom Line
Based on current evidence, maintaining a healthy diet low in foods that promote TMA production (such as red meat, eggs, and certain supplements) may help reduce diabetes risk, though this is not yet a proven treatment. Moderate confidence: eating more plant-based foods and fiber may promote healthier gut bacteria composition. Low to moderate confidence: future IRAK4-blocking drugs or FMO3 inhibitors might help treat diabetes, but these are still in research stages. Anyone with type 2 diabetes should continue following their doctor’s current treatment plan while this research develops.
People with type 2 diabetes or at high risk for developing it should be aware of this research, as it may eventually lead to new treatment options. People with a family history of diabetes might benefit from dietary changes that support healthy gut bacteria. However, this research is not yet ready to change standard medical practice. People taking medications for diabetes should not change their treatment based on this review alone. Researchers and pharmaceutical companies should prioritize developing and testing new treatments based on this pathway.
If new drugs targeting IRAK4 or TMAO production are developed, it will likely take 5 to 10 years of human testing before they become available. Dietary changes to support healthy gut bacteria might show benefits within weeks to months, though individual results vary. Most experts expect that personalized treatment based on individual gut bacteria profiles will become available within 5 to 15 years as technology improves.
Frequently Asked Questions
Can changing my diet reduce TMAO levels and help prevent type 2 diabetes?
Eating less red meat, eggs, and carnitine-rich foods may lower TMAO production since gut bacteria create TMA from these nutrients. However, human studies confirming this approach prevents diabetes are still limited. Increasing fiber and plant-based foods supports healthier gut bacteria, which may help.
What foods should I avoid if I’m worried about TMAO and diabetes?
Foods high in choline (eggs, red meat, organ meats, dairy) and carnitine (red meat, supplements) promote TMA production by gut bacteria. Reducing these while increasing vegetables, whole grains, and fermented foods may support better gut health and lower inflammation.
Is TMAO testing available to check my diabetes risk?
TMAO blood tests exist but are not yet standard for diabetes screening or management. Most doctors don’t routinely measure TMAO because treatments specifically targeting it are still experimental. Talk to your doctor about whether testing makes sense for your situation.
How soon will new diabetes treatments based on this research be available?
Drugs targeting IRAK4 or TMAO production are still in research stages and likely 5 to 10 years away from availability. Dietary changes supporting healthy gut bacteria can be implemented now, though individual results vary based on your unique microbiome.
Does everyone with high TMAO levels develop type 2 diabetes?
No. People have different gut bacteria and genetic backgrounds, so TMAO affects individuals differently. High TMAO increases diabetes risk but doesn’t guarantee development. Other factors like genetics, exercise, and overall diet also play important roles.
Want to Apply This Research?
- Track daily intake of choline-rich foods (eggs, red meat, dairy, supplements) and correlate with blood sugar readings and energy levels over 4-week periods to identify personal patterns.
- Log meals containing high choline or carnitine content and experiment with replacing some of these foods with plant-based alternatives, tracking any changes in blood sugar control or energy levels.
- Create a 12-week food and glucose tracking log, noting which dietary patterns correlate with better insulin sensitivity, then adjust gut-health-supporting foods (fiber, fermented foods) accordingly and monitor trends monthly.
This article reviews emerging research on gut bacteria and type 2 diabetes. The findings are primarily from laboratory and animal studies, not yet proven in large human trials. Do not change your diabetes medications or treatment plan based on this information. If you have type 2 diabetes or are at risk, consult your healthcare provider before making significant dietary changes or considering experimental treatments. TMAO testing and IRAK4-targeting drugs are not yet standard medical care. This content is for educational purposes and should not replace professional medical advice.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.